Calcitriol 25mcg 1 Capsule [Prescription Required]

TREATMENT AND PREVENTION OF VITAMIN D DEFICIENCY STATES AND HYPOCALCAEMIA IN DISORDERS SUCH AS HYPOPARATHYROIDISM AND SECONDARY HYPOPARATHYROIDISM. IT IS IN THE TREATMENT OF OSTEOPOROSIS.

Place of Origin

VIETNAM

Product Usage

THE USUAL INITIAL ADULT ORAL DOSE IS 0.25mcg (1 CAPSULE) DAILY ON ALTERNATE DAYS ARE GIVEN, INCREASED IF NECESSARY, IN STEPS OF 0.25mcg (1 CAPSULE) AT INTERVALS OF 2 TO 4 WEEKS, TO USUAL DOSE OF 0.25mcg (2 CAPSULE) TO 1mcg (4 CASULES DAILY). FOR MODERATE TO SEVERE SECONDARY HYPERRATHYROIDISM IN DIALYSIS PATIENTS, INITIAL DOSE OF 0.25mcg (2 CAPSULE) TO 4mcg (8 CAPSULE) HAVE BEEN GIVEN THREE TIMES A WEEK, INCREASED IF NECESSARY IN STEPS OF 0.25mcg (1 CAPSULE) TO 1mcg (4 CAPSULE) AT INTERVALS OF 2-4 WEEKS A MAXIMUM OF 8mcg (16 CAPSULES) GIVEN THREE TIMES A WEEK. IN ESTABLISHED POSTMENOPOSAL OSTEOPOROSIS, A DOSE OF 0.25mcg (1 CAPSULE) TWICE DAILY RECOMMENDED. WHEN VITAMIN D SUBTANCES ARE GIVEN IN PHARMACOLOGICAL DOSES, DOSAGE MUST BE INDIVIDUALIZED FOR EACH PATIENT, AND SHOULD BE BASED ON REGULAR MONITORING OF PLASMA-CONCENTRATIONS (INITIALLY ONCE OR TWICE WEEKLY), TO OPTIMIZE CLINICAL RESPONSE AND AVOID HYPERCALCAEMIA.

Ingredients

CALCITRIOL

Warnings

1. ALL KINDS OF DESEASES RELATED TO HYPERCALCEMIA. 2. PATIENTS WITH HISTORY OF HYPERSENSITIVITY TO THIS DRUG OR ANY COMPONENTS OF THIS DRUG. 3. PATIENTS WITH EVIDENCE OF VITAMIN D TOXICITY.

Width

1

Height

1

Depth

1